rupiya.io
⠋Loading...
0%
❯ Aggregating market cap data...
Viyash Scientific Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Viyash Scientific Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹395 Cr | ₹443 Cr | ₹606 Cr | |||||||||
| Expenses | ₹389 Cr | ₹425 Cr | ₹550 Cr | |||||||||
| Operating Profit | ₹6 Cr | ₹18 Cr | ₹56 Cr | |||||||||
| OPM % | 2.0% | 4.0% | 9.0% | |||||||||
| Other Income | ₹-54 Cr | ₹48 Cr | ₹14 Cr | |||||||||
| Depreciation | ₹29 Cr | ₹32 Cr | ₹46 Cr | |||||||||
| Interest | ₹34 Cr | ₹43 Cr | ₹38 Cr | |||||||||
| Profit Before Tax | ₹-110 Cr | ₹-8 Cr | ₹-14 Cr | |||||||||
| Tax | ₹-110 Cr | ₹-8 Cr | ₹-14 Cr | |||||||||
| Net Profit | ₹-110 Cr | ₹-12 Cr | ₹-16 Cr | |||||||||
| EPS (₹) | -8.1 | -0.7 | -0.8 | |||||||||
| Dividend Payout % | 0% | 0% | 0% |
Register free to see 9 more years.
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹375 Cr | ₹367 Cr | ₹333 Cr | ₹346 Cr | ||||||||
| Expenses | ₹365 Cr | ₹370 Cr | ₹341 Cr | ₹331 Cr | ||||||||
| Operating Profit | ₹10 Cr | ₹-3 Cr | ₹-8 Cr | ₹15 Cr | ||||||||
| OPM % | 3.0% | -1.0% | -2.0% | 4.0% | ||||||||
| Depreciation | ₹14 Cr | ₹15 Cr | ₹14 Cr | ₹15 Cr | ||||||||
| Interest | ₹10 Cr | ₹11 Cr | ₹10 Cr | ₹13 Cr | ||||||||
| Net Profit | ₹-10 Cr | ₹-92 Cr | ₹-35 Cr | ₹-7 Cr | ||||||||
| EPS (₹) | -0.4 | -3.8 | -1.4 | -0.3 |
Register free to see 8 more quarters.
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹27 Cr | ₹30 Cr | ₹48 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹30 Cr | ₹61 Cr | ₹898 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹418 Cr | ₹473 Cr | ₹312 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹148 Cr | ₹343 Cr | ₹265 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹623 Cr | ₹908 Cr | ₹1,523 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹238 Cr | ₹474 Cr | ₹586 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹0 Cr | ₹59 Cr | ₹428 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹342 Cr | ₹336 Cr | ₹485 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹623 Cr | ₹908 Cr | ₹1,523 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Register free to see 9 more years.
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2015 | ₹-45 Cr | ₹-81 Cr | ₹146 Cr | — |
| Mar 2016 | ₹-24 Cr | ₹-157 Cr | ₹179 Cr | — |
| Mar 2017 | ₹0 Cr | ₹-310 Cr | ₹309 Cr | — |
| Mar 2018 | ||||
| Mar 2019 | ||||
| Mar 2020 | ||||
| Mar 2021 | ||||
| Mar 2022 | ||||
| Mar 2023 | ||||
| Mar 2024 | ||||
| Mar 2025 |
Register free to see 9 more years.
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +8.45% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.74% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -5.78% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +7.74% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +3.69% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.